2022 International Congress » Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Meeting: 2022 International Congress

A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress

R. Pahwa, A. Ellenbogen, R. Elble, K. Bankole, T. Dam, J. Fratantonio, J. Gaiha-Rohrbach, M. Qin, S. Garafola, M. Gerbasi, H. Colquhoun (Kansas City, USA)

Clinical effectiveness and economic impact of transcutaneous afferent patterned stimulation therapy for essential tremor in a real-world setting: protocol for a pragmatic trial

D. Dai, J. Fernandes, LA. Ramel, H. Coetzer, V. Zraick, A. Samiian, L. Hennum (Woonsocket, USA)

Effects of venlafaxine on neuropsychiatric and motor symptoms in patients with progressive supranuclear palsy

M. Zeitzschel, M. Maheu, T. Donner, C. Gerloff, A. Gulberti, M. Pötter-Nerger (Hamburg, Germany)

Electrical stimulation of muscle afferents for tremor reduction in essential tremor patients

M. González Sánchez, JR. Pérez Sánchez, A. Pascual Valdunciel, F. Oliveira Barroso, S. Muceli, B. Adán-Barrientos, V. Escobar-Segura, M. Ki Jung, A. Muñoz González, A. Schneider, KP. Hoffmann, D. Farina, JL. Pons, FJ. Grandas Pérez (Madrid, Spain)

Expanding the armamentarium of clinical use of apomorphine in movement disorders.

S. Bansal, JR. Chai, M. Jog (London, Canada)

Is there a role for safinamide in atypical parkinsonian syndromes?

A. Silva, M. Rodrigues (Braga, Portugal)

Patient-Specific Outcomes of Transcutaneous Afferent Patterned Stimulation with Varying Frequencies for Essential Tremor and Parkinson’s Disease

A. Kent, H. Kim, D. Khosla, K. Rosenbluth (Foster City, USA)

Safety and Efficacy of Verdiperstat, a Novel Myeloperoxidase Inhibitor, in MSA

I. Qureshi, V. Wirtz, L. Brady, J. Ellison, A. Ellenbogen, R. Freeman, G. Höglinger, H. Kaufmann, A. Lang, P. Low, W. Meissner, P. Millar Vernetti, H. Morris, J. Palma, S. Perlman, W. Poewe, J. Schmahmann, K. Seppi, W. Singer, S. Vernino, G. Wenning (New Haven, USA)

Safety and tolerability of Nilotinib in patients with Huntington’s disease

K. Anderson (Washington, USA)

Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies

F. Pagan, Y. Torres-Yaghi, M. Hebron, R. Turner, B. Wilmarth, S. Matar, D. Ferrante, J. Ahn, C. Moussa (Washington, USA)

Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia

D. Bettoun, T. Galas, D. Schecter, N. Ruiz, R. Clayton, J. Farmer (Bala Cynwyd, USA)

Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study

G. Francisco, W. Feng, M. Munin, K. Ngo, M. Schwartz, M. Sadeghi, A. Zuzek, A. Esquenazi (Houston, USA)

« View all sessions from the 2022 International Congress.